异丙基亚氨基吡咯烷 | 1004-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 中文名称: 异丙基亚氨基吡咯烷
• 英文名称: isopropylimino-2-pyrrolidine
• 英文别名: isopropyl-iminopyrrolidine；N-propan-2-yl-3,4-dihydro-2H-pyrrol-5-amine
• CAS: 1004-25-7
• 化学式: C₇H₁₄N₂
• mdl: MFCD21641010
• 分子量: 126.202
• InChiKey: QZKQEYBMTHAMPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  三乙基铝 、 异丙基亚氨基吡咯烷 以 正己烷 为溶剂， 以66%的产率得到diethyl aluminium isopropyl-iminopyrrolidinate
  参考文献：
  名称：

  铝的异亚氨基吡咯烷酸盐†

  摘要：

  一系列 亚氨基吡咯烷（ip）化合物以极高的收率合成，作为用于原子层沉积的新型有机金属前体的潜在配体。这些配体背后的想法是碳二亚胺 （CDI）不会出现四元解插 碳被束缚于一种螯合氮。对我们有利的是，ip配体中的熔点趋势很明显，并且在ip配体与TMA 或者 茶。烷烃消除反应在室温下发生，以高收率得到清洁的产物。收集化合物7 [ipipAlMe 2 ]，12 [tbipAlMe 2 ]和14 [sbipAlEt 2 ]的晶体结构，表明杂多铝物种为二聚体。在每种化合物收集的质谱图中也很明显，因为母峰是二聚体峰减去甲基峰。对所有ipAlMe 2进行了热解研究种观察几天内在等温线下的分解。监测甲基峰的衰减，以其相对于溶液中TMS的比率进行监测，并显示为一级分解。从这些研究中可以明显看出，nbip（9），iso-bip（10）和tbip（12）是最稳定的复合物，半衰期分别为24.8、9.00和10.3天。

  DOI：

  10.1039/c0dt00267d
• 作为产物：
  描述：

  copper(I) isopropylimino-2-pyrrolidinate 以 neat (no solvent) 为溶剂， 生成 异丙基亚氨基吡咯烷 、 铜
  参考文献：
  名称：

  Copper Iminopyrrolidinates: A Study of Thermal and Surface Chemistry

  摘要：

  Several copper(I) iminopyrrolidinates have been evaluated by thermogravimetric analysis (TGA) and solution based H-1 NMR studies to determine their thermal stability and decomposition mechanisms. Iminopyrrolidinates were used as a ligand for copper(I) to block previously identified decomposition routes of carbodiimide deinsertion and beta-hydrogen abstraction. The compounds copper(I) isopropyl-iminopyrrolidinate (1) and copper(I) tert-butyl-iminopyrrolidinate (2) were synthesized for this study, and compared to the previously reported copper(I) tert-butyl-imino-2,2-dimethylpyrrolidinate (3) and the copper(I) guanidinate [Me2NC((PrN)-Pr-1)(2)Cu](2) (4). Compounds 1 and 2 were found to be volatile yet susceptible to decomposition during TGA. At 165 degrees C in C6D6, they had half-lives of 181.7 h and 23.7 h, respectively. The main thermolysis product of 1 and 2 was their respective protonated iminopyrrolidine ligand. beta-Hydrogen abstraction was proposed for the mechanism of thermal decomposition. Since compound 3 showed no thermolysis at 165 degrees C, it was further studied by chemisorption on high surface area silica. It was found to eliminate an isobutene upon chemisoption at 275 degrees C. Annealing the sample at 350 degrees C showed further evidence of the decomposition of the surface species, likely eliminating ethene, and producing a surface bound methylene diamine.

  DOI：

  10.1021/ic3021035

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Chow Ken

  公开号：US20110178143A1

  公开（公告）日：2011-07-21

  Disclosed herein is a compound having a structure compositions, methods, and medicaments related thereto are also disclosed.

  本文披露了一种具有结构的化合物，同时还披露了相关的组成、方法和药物。
• ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE
  申请人：The Regents of the University of California

  公开号：US20160264566A1

  公开（公告）日：2016-09-15

  Provided herein, inter alia, are methods and compositions for inhibiting αvβ1 integrin and for treating fibrosis.

  本文提供了抑制αvβ1整合素和治疗纤维化的方法和组合物等内容。
• Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH
  申请人：Wooley Karen L.

  公开号：US20130210156A1

  公开（公告）日：2013-08-15

  Described herein are optical agents, including compositions, preparations and formulations, for monitoring the pH of a fluid. Optical agents described herein include photonic nanostructures and nanoassemblies including supramolecular structures, such as shell cross-linked micelles, that incorporate at least one linking group comprising one or more photoactive moieties that provide functionality as exogenous agents for a range of pH monitoring applications. Optical agents described herein comprise supramolecular structures having linking groups imparting useful optical and structural functionality. In an embodiment, for example, the presence of linking groups function to covalently cross link polymer components to provide a cross-linked shell stabilized supramolecular structure, and also impart useful optical functionality, for example by functioning as a fluorophore.
• CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY
  申请人：MONOPAR THERAPEUTICS INC.

  公开号：US20180098967A1

  公开（公告）日：2018-04-12

  The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
• US8426454B2
  申请人：——

  公开号：US8426454B2

  公开（公告）日：2013-04-23